David A. Siegel Opti Nose, Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$3.2 - $4.98 $120,320 - $187,248	-37,600 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.69 - $7.09 $87,453 - $168,033	23,700 Added 170.5%	37,600 $147,000
Q2 2020 Aug 14, 2020	SELL	$3.58 - $7.44 $1,790 - $3,720	-500 Reduced 3.47%	13,900 $103,000
Q1 2020 May 15, 2020	BUY	$3.49 - $9.2 $50,256 - $132,480	14,400 New	14,400 $65,000
Q3 2019 Nov 14, 2019	SELL	$4.75 - $8.38 $63,175 - $111,454	-13,300 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$6.4 - $10.94 $55,680 - $95,178	-8,700 Reduced 39.55%	13,300 $94,000
Q1 2019 May 15, 2019	BUY	$6.1 - $10.3 $1,220 - $2,060	200 Added 0.92%	22,000 $227,000
Q4 2018 Feb 14, 2019	BUY	$5.84 - $11.92 $127,312 - $259,856	21,800 New	21,800 $135,000

88.3M

Ticker OPTN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 83,277,504
Market Cap $44.1M
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.